The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis

Cancer Research

Volumn 60, Issue 18, 2000, Pages 5040-5044

  Jacoby, R F ^a   Seibert, K ^a   Cole, C E ^a   Kelloff, G ^a   Lubet, R A ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; COLON CANCER; CONTROLLED STUDY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI; ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; COMPARATIVE STUDY; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; ISOENZYMES; MALE; MICE; MICE, INBRED C57BL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; SUBSTRATE SPECIFICITY; SULFONAMIDES; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOXANE B2;

EID: 0034665122     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Approaches to the development and marketing approval of drugs that prevent cancer
2. Polyposis syndromes
3. Molecular diagnostic methods in cancer genetics
4. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
5. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
6. Chemoprevention of spontaneous intestinal adenomas in the Min/Apc mouse model by the nonsteroidal anti-inflammatory drug piroxicam
7. Aspirin and the potential role of prostaglandins in colon cancer
8. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
9. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
10. Aspirin and the risk of colorectal cancer in women
11. NSAID use and decreased risk of gastrointestinal cancers
12. Cyclooxygenase NSAIDs, and colorectal cancer
13. Aspirin use and reduced risk of fatal colon cancer
14. Aspirin use and potential mechanisms for colorectal cancer prevenlion
15. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors
16. 2 in human colon cancer cells
17. Alterations in cellular adhesion and apoptosis in epithelial ceils overexpressing prostaglandin endoperoxide synthase 2
18. Localized gene action controlling intestinal neoplasia in mice
19. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
20. Suppression of intestinal polyposis in ApeΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
21. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
22. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis
23. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Ape mutant embryos
24. Rapid and sensitive method for determination of piroxicam in dog, rat and human plasma by high-performance liquid chromatography
25. Random allocations in comparative experiments of known size: Balance without blocking
26. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
27. Increased cyclooxygenase-2 mRNA and protein in Min mice tumors
28. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
29. Chemoprevention of colon cancer by specific cyclo-oxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
30. The specific cyclooxygenase-2 inhibitor, celecoxib, causes adenoma regression in the Apc mutant Min mouse
31. Effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis